Cargando…
A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor
BACKGROUND: This study evaluated the human abuse potential of solriamfetol (formerly JZP-110), a selective dopamine and norepinephrine reuptake inhibitor with robust wake-promoting effects. METHODS: Adults with a recent history of recreational polydrug use, including stimulants, and who met criteria...
Autores principales: | Carter, Lawrence P, Henningfield, Jack E, Wang, Y Grace, Lu, Yuan, Kelsh, Debra, Vince, Bradley, Sellers, Edward |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247449/ https://www.ncbi.nlm.nih.gov/pubmed/30269642 http://dx.doi.org/10.1177/0269881118796814 |
Ejemplares similares
-
Effects of solriamfetol on on‐the‐road driving in participants with narcolepsy: A randomised crossover trial
por: Vinckenbosch, Frederick, et al.
Publicado: (2022) -
Fatigue-related impairments in oculomotor control are prevented by norepinephrine-dopamine reuptake inhibition
por: Connell, Charlotte J. W., et al.
Publicado: (2017) -
A Randomized, Double‐Blind, Placebo‐ and Positive‐Controlled, 4‐Period Crossover Study of the Effects of Solriamfetol on QTcF Intervals in Healthy Participants
por: Zomorodi, Katie, et al.
Publicado: (2020) -
Abuse potential of mirogabalin in recreational polydrug users
por: Mendell, Jeanne, et al.
Publicado: (2019) -
Pharmacodynamic and pharmacokinetic assessment of electronic cigarettes, combustible cigarettes, and nicotine gum: implications for abuse liability
por: Stiles, Mitchell F., et al.
Publicado: (2017)